Republished with permission from Common Dreams, by Jake Johnson

Republican Sen. Mike Crapo of Idaho blocked Sen. Bernie Sanders’ attempt Wednesday to force a vote on legislation that would slash prescription drug prices, thwarting the Vermont senator’s effort to fast-track the new bill as the pharmaceutical industry rushes to hike costs in the new year.

Sanders, chair of the Senate Budget Committee, requested unanimous consent to proceed to debate and a vote on the Cutting Medicare Prescription Drug Prices in Half Act, a measure he introduced earlier Wednesday alongside Sen. Amy Klobuchar (D-Minn.).

If passed, the bill would bring the prices of drugs covered by Medicare into line with what the Department of Veterans Affairs (VA) or the Federal Supply Schedule pay for the same medications. According to a 2017 Government Accountability Office study, the VA “paid an average of 54% less per unit than Medicare” for a sample of hundreds of brand-name and generic drugs.

But Crapo—a major recipient of pharmaceutical and insurance industry donations—objected to Sanders’ request to advance the legislation, claiming it would usher in “more bureaucracy.” The Idaho Republican is the lead sponsor of a more industry-friendly bill titled the Lower Costs, More Cures Act, which advocates a “market-based approach” to lowering drug prices.

In a floor speech on Wednesday, Sanders said that “for far too long, it has not been Congress that has been regulating the pharmaceutical industry, it has been the pharmaceutical industry that has been regulating Congress.”

“All over this country, the American people are asking a simple question: How many people need to die, how many people need to get unnecessarily sicker, before Congress is prepared to take on the greed of the prescription drug industry?” said the Vermont senator. “Enough is enough. A lifesaving prescription drug does not mean anything if you cannot afford to buy that drug.”

“We cannot allow the pharmaceutical industry to charge the American people, by far, the highest prices in the world for prescription drugs,” Sanders added.

The attempt by Sanders and Klobuchar to hold a vote on their standalone drug-price legislation came as pharmaceutical firms—which lobbied aggressively against the Build Back Better package—continued to raise the costs of medications that treat a range of serious conditions, from cancer to heart disease to HIV.

An analysis released last week by Patients for Affordable Drugs showed that pharma companies have increased the prices of 742 medications so far this year.

“Of the 742 drugs that the industry raised prices on, 92% were on brand-name drugs, one in four exceeded the most recent rate of inflation available in early January, and 93% exceeded the projected inflation rate for 2023, 2.3%,” the group found.

David Mitchell, a cancer patient and the founder of Patients for Affordable Drugs, said in a statement that “right now, Big Pharma has unlimited pricing power on brand-name drugs.”

“Consistently,” Mitchell continued, “the industry proves it only cares about maximizing profit—not public health—and will continue to raise prices as high as it thinks possible without regard to the millions of Americans who are hurt by high drug prices.”